Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | TERT | O14746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL771416 | 0.92 | HSD11B1 (0.34) | LTA4HOPRM1OPRK1 | |
| SCHEMBL771319 | 0.86 | — | — | |
| SCHEMBL26981363 | 0.86 | — | — | |
| SCHEMBL8860927 | 0.79 | NPC1 (0.31) | — | |
| SCHEMBL70520 | 0.78 | HRH3 (0.44) | LTA4H | |
| SCHEMBL14067219 | 0.76 | OPRM1 (0.34) | LTA4HOPRM1OPRK1LMNATERT | |
| SCHEMBL19014577 | 0.76 | DPP4 (0.34) | LTA4HOPRM1OPRK1LMNATERT | |
| SCHEMBL15543851 | 0.75 | — | — | |
| SCHEMBL15806908 | 0.74 | ACHE (0.47) | OPRK1 | |
| SCHEMBL12714801 | 0.74 | DRD2 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10584128-B2 | Bicyclic dihydropyrimidine-carboxamide derivatives as Rho-Kinase inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2020-03-10 | — | — | US | claimed |
| EP-3558999-A1 | BICYCLIC DIHYDROPYRIMIDINE-CARBOXAMIDE DERIVATIVES AS RHO-KINASE INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2019-10-30 | — | — | EP | claimed |
| WO-2018115383-A1 | BICYCLIC DIHYDROPYRIMIDINE-CARBOXAMIDE DERIVATIVES AS RHO-KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2018-06-28 | — | — | WO | claimed |
| US-20180170939-A1 | BICYCLIC DIHYDROPYRIMIDINE-CARBOXAMIDE DERIVATIVES AS RHO- KINASE INHIBITORS | CHIESI FARMACEUTISI S.p.A. (IT) | 2018-06-21 | — | — | US | claimed |
| EP-3004087-A1 | DERIVATIVES OF [1, 2, 4]TRIAZOLO [4, 3 - A]PYRIDINE AS P38 - MAP KINASE INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2016-04-13 | — | — | EP | claimed |
| WO-2014194956-A1 | DERIVATIVES OF [1, 2, 4] TRIAZOLO [4, 3 - A] PYRIDINE AS P38 - MAP KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2014-12-11 | — | — | WO | claimed |
| EP-1838712-B8 | PYRAZOLOPYRIMIDINE COMPOUNDS AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2011-10-12 | — | — | EP | claimed |
| EP-1838712-B1 | PYRAZOLOPYRIMIDINE COMPOUNDS AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2011-03-09 | — | — | EP | claimed |
| US-20080108613-A1 | Pyrazolopyrimidine Compounds as Antitumor Agents | ASTRAZENECA AB (SE) | 2008-05-08 | — | — | US | claimed |
| EP-1838712-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AS ANTITUMOR AGENTS | AstraZeneca AB (SE) | 2007-10-03 | — | — | EP | claimed |
| WO-2006064196-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2006-06-22 | — | — | WO | claimed |
| US-20240166669-A1 | QUINAZOLINE AMINE DERIVATIVES AS KRAS INHIBITORS | NIKANG THERAPEUTICS, INC. | 2024-05-23 | — | — | US | disclosed |
| EP-4301363-A1 | QUINAZOLINE AMINE DERIVATIVES AS KRAS INHIBITORS | Nikang Therapeutics, Inc. (US) | 2024-01-10 | — | — | EP | disclosed |
| CN-117255684-A | Quinazolinamine derivatives as KRAS inhibitors | 尼坎治疗公司 | 2023-12-19 | — | — | CN | disclosed |
| CN-113004278-B | Bicyclic heterocycles as FGFR inhibitors | 因赛特控股公司 | 2023-07-21 | — | — | CN | disclosed |
| WO-2006064196-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2006-06-22 | — | — | WO | disclosed |
| EP-0450066-B1 | CARBOSTYRIL DERIVATIVES | OTSUKA PHARMA CO LTD (JP) | 1996-09-11 | — | — | EP | disclosed |
| US-5401740-A | FOR INHIBITING PLATELET AGGREGATION | OTSUKA PHARMACEUTICAL CO. (JP) | 1995-03-28 | — | — | US | disclosed |
| US-5227381-A | Anticoagulant | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1993-07-13 | — | — | US | disclosed |
| EP-0450066-A1 | CARBOSTYRIL DERIVATIVES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1991-10-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180170939-A1 | BICYCLIC DIHYDROPYRIMIDINE-CARBOXAMIDE DERIVATIVES AS RHO- KINASE INHIBITORS | ROCK1, ROCK2, CIT | LTA4H 1283/4885OPRM1 4610/4885OPRK1 3583/4885 |
| US-20240166669-A1 | QUINAZOLINE AMINE DERIVATIVES AS KRAS INHIBITORS | KRAS, NRAS, HRAS | LTA4H 4413/4885OPRM1 3744/4885OPRK1 2381/4885 |
| US-20080108613-A1 | Pyrazolopyrimidine Compounds as Antitumor Agents | ERBB2, ERBB3, ERBB4 | LTA4H 4421/4885OPRM1 1792/4885OPRK1 1226/4885 |
| US-10584128-B2 | Bicyclic dihydropyrimidine-carboxamide derivatives as Rho-Kinase inhibitors | ROCK1, ROCK2, CIT | LTA4H 1283/4885OPRM1 4610/4885OPRK1 3583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.